United States· US:0069-1510_a13e8012-656c-4e2a-b43a-2f3366a28ffb
HYMPAVZI
A medicinal product containing marstacimab-hncq, registered in United States by Pfizer Laboratories Div Pfizer Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- marstacimab-hncq
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1100691510011 SYRINGE in 1 CARTON (0069-1510-01) / 1 mL in 1 SYRINGE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimab-hncq in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandHympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG
- CzechiaHYMPAVZIPfizer Europe MA EEIG, Bruxelles
- IcelandHympavziPfizer Europe MA EEIG*
- FinlandHympavziPfizer Europe MA EEIG
- BelgiumHympavzi 150 mgPfizer Europe MA
- NetherlandsHympavzi 150 mg oplossing voor injectie in een voorgevulde penPfizer Europe MA EEIG
- PolandHympavziPfizer Europe MA EEIG
- SwedenHympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspennaPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/143542ae-bdba-4199-b711-34f738875800 GET /v1/drugs/143542ae-bdba-4199-b711-34f738875800?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": null
},
"productid": "0069-1510_a13e8012-656c-4e2a-b43a-2f3366a28ffb",
"productndc": "0069-1510",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "MARSTACIMAB",
"proprietary_name": "HYMPAVZI",
"active_ingred_unit": "mg/mL",
"application_number": "BLA761369",
"marketing_category": "BLA",
"nonproprietary_name": "marstacimab-hncq",
"start_marketing_date": "20251016",
"active_numerator_strength": "150"
}See everything about marstacimab-hncq.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.